Agios' mitapivat successful in late-stage study in rare blood disorder

• A Phase 3 clinical trial, ACTIVATE, evaluating Agios Pharmaceuticals' (NASDAQ:AGIO) mitapivat in adults with pyruvate kinase (PK) deficiency who do not receive regular transfusions met the primary endpoint.
• Specifically, 40% of treated patients achieved a hemoglobin response at weeks 16, 20 and 24